Skip to main content
Wolfson Institute of Population Health
  1. WIPH
  2. People
  3. Profiles

Professor Alastair Noyce, BMedSci, MB BS, MSc, MRCP, PhD, FHEA

Alastair

Professor in Neurology and Neuroepidemiology and Consultant Neurologist

Email: a.noyce@qmul.ac.uk

Profile

I am a Professor in Neurology and Neuroepidemiology in the Centre for Preventive Neurology (CPN), in the Wolfson Institute of Population Health, Queen Mary University of London (QMUL). I am the deputy lead for the CPN and a Consultant Neurologist at Barts Health NHS Trust.

I graduated from Barts and the London (QMUL) in 2007 and I pursued integrated training via the Foundation Academic Programme and an NIHR Academic Clinical Fellowship at UCL. Between 2012-2016 I undertook a PhD in Neuroscience at UCL and between 2014-2016 I undertook an MSc in Epidemiology at London School of Hygiene and Tropical Medicine. I re-joined QMUL and the PNU in 2017 to lead the Parkinson’s programme of work.

My research interests are Parkinson’s disease and other neurodegenerative disorders, particularly early identification and epidemiological aspects, including environmental, clinical and genetic determinants. I am the co-principal investigator of the PREDICT-PD study, principal investigator for the East London Parkinson’s Disease project and chief investigator for the Access-PD study.

I am a member of the International Parkinson and Movement Disorder Society (MDS). I graduated from the MDS LEAP leadership programme in 2020, and then became a member of the faculty for the LEAP, teaching leadership skills to early career movement disorders specialists around the world. I am the Chair of the MDS Epidemiology Study Group, a member of the MDS Early Onset PD Study Group and the Equality of Access to Care Committee. I on the Global Parkinson’s Genetics Program (GP2) and lead two of its working groups, focusing on Training and Networking and Prodromal PD. I am Associate Editor for the Journal of Parkinson’s Disease.

Away from neurodegenerative disease, I am interested in the emerging link between recreational use of nitrous oxide (laughing gas) and neurological harm. I have led the drafting of national guidance for managing the range of neurological conditions associated with nitrous oxide, as well as describing the clinical manifestations in patients in order to raise awareness amongst healthcare workers.

 

Research

Research Interests:

Neurology

Epidemiology

Genetics

Predictive models

Clinical research

Publications

  • Kenny J, Torricelli R, Zirra A et al. (2026). Corrigendum to “A cross-sectional exploration of the relationship between Parkinson's disease and peripheral blood immune cells in an ethnically diverse East London population” [Journal of the Neurological Sciences 484 (2026) 125785]. nameOfConference


  • Lange LM, Fang Z-H, Makarious MB et al. (2026). Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications. nameOfConference


    QMRO: qmroHref
  • Schwarzschild MA, Macklin EA, Morain SR et al. (2026). A paradoxical plus for Parkinson's in UK's new ‘generational smoking ban’. nameOfConference


  • Jones L, Cerquera-Cleves C, Schuh AFS et al. (2026). Population Attributable Risk in Alzheimer and Parkinson Diseases. nameOfConference


  • Oosterhof TH, Mitchell E, Ascherio A et al. (2026). Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson’s disease. nameOfConference


  • Virameteekul S, Bonini I, Campese N et al. (2026). Phenoconversion in Pure Autonomic Failure. nameOfConference


  • Azoidou V, Bhadra E, Camboe E et al. (2026). Perceived consequences and catastrophising help explain health-related quality of life in Parkinson's disease. A cross-sectional study. nameOfConference


  • Azoidou V, Bhadra E, Camboe E et al. (publicationYear). Sternum-worn vibrotactile device in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot trial. nameOfConference


  • Dey KC, Bhadra E, Zirra A et al. (2026). Recruitment strategies in a diverse Parkinson’s disease cohort: lessons from the East London Parkinson’s Disease Project. nameOfConference


  • Flores-Ocampo V, Zirra A, Tay YW et al. (2026). The Global Parkinson's Genetics Program (GP2): Advancing genetic discovery and capacity building worldwide. nameOfConference


    QMRO: qmroHref
View profile publication page

Supervision

Jonggeol Kim, Global Parkinson's Genetics Programme, Genetic Determinants of Parkinson's Disease

Benjamin Jacobs (subsidiary supervisor), MRC, Genetic Association study in individuals of Diverse Ancestral backgrounds with Multiple Sclerosis (ADAMS)

Alex Zirra, The Medical College of St Bartholomew’s Hospital Trust, Cognitive features of Parkinson’s disease in a diverse population

Ellen Camboe, Barts Charity, Parkinson’s Disease Psychosis in a Diverse Population

Harneek Chohan, Early clinical and biological markers in Parkinson's Disease

Back to top